Troglitazone Induces Expression of PPARγ in Liver
- 1 September 1999
- journal article
- Published by Elsevier BV in Molecular Cell Biology Research Communications
- Vol. 2 (3), 202-208
- https://doi.org/10.1006/mcbr.2000.0176
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanismBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1999
- Thiazolidinediones Downregulate Stearoyl-CoA Desaturase 1 Gene Expression in 3T3-L1 AdipocytesDiabetes, 1997
- TNF-α-Induced Insulin Resistance In Vivo and Its Prevention by TroglitazoneDiabetes, 1997
- Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDMDiabetes, 1997
- Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.JCI Insight, 1996
- Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patientsDiabetologia, 1996
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like CellsPublished by Elsevier BV ,1995
- A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitusDiabetes Research and Clinical Practice, 1991
- In vitro studies on the action of CS-045, a new antidiabetic agentMetabolism, 1990